At the International Liver Congress, Sophie Lotersztajn was awarded for her carrier and her input in hepatology and liver pathophysioplogy.

She is recognized for her pionneer basic and translational work on liver fibrosis, that led to the identification of new targets and pathways for antifibrotic therapy. She has chaired several national and international boards, and coordinated numerous national grant programs on liver research. 

Learn more:

EASL : https://easl.eu/event/international-liver-congress-2022/awards/ 

Learn more about the work of the INVolVED team : https://cri1149.fr/equipes/lotersztajn-gilgenkrantz/